Major Scope

  •  Lung Cancer
  •  Colorectal Cancer
  •  Pancreatic Cancer
  •  Breast Cancer
  •  Prostate Cancer
  •  Liver Cancer
  •  Leukemia
  •  Bladder Cancer
  •  Kidney Cancer
  •  Endometrial Cancer
  •  Oncology Case Reports
  •  Radiation Therapy

Abstract

Citation: Clin Oncol. 2016;1(1):1035.DOI: 10.25107/2474-1663-v1-id1035

The Da Vinci Xi in Robotic Radical Prostatectomy- An Evolution in Learning and Technique

Goonewardene SS and Cahill D

The Royal Free Hospital and UCL, London
The Royal Marsden, London

*Correspondance to: Goonewardene SS 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: The Da Vinci Xi robot has been introduced as the successor to the Si platform. The promise of the Xi is to open the door to new surgical procedures. For robotic assisted radical prostatectomy (RARP)/pelvic surgery the potential is better vision and longer instruments. How has the Xi impacted on operative and pathological parameters as indicators of surgical performance?
Methods: This is a comparison of an initial series of 42 RARPs with the Xi system in 2015 with a series using the Si system immediately before Xi uptake in the same calendar year and an Si series by the same surgeon synchronously as the Xi series using operative time, blood loss and positive margins as surrogates of surgical performance.
Results: Subjectively and objectively there is a learning curve to Xi uptake in longer operative times but no impact on T2 positive margins which are the most reflective single measure of RARP outcomes. Subjectively the vision of the Xi is inferior to the Si system and the integrated diathermy system and automated set up are quirky. All require experience to overcome.
Conclusion: There is a learning curve to progress from the Si to Xi Da Vinci surgical platforms but this does not negatively impact outcome.

Keywords:

Robotic surgery; Davinci Xi

Cite the Article:

Goonewardene SS, Cahill D. The Da Vinci Xi in Robotic Radical Prostatectomy- An Evolution in Learning and Technique. Clin Oncol. 2016; 1: 1035.

Journal Basic Info

  • Impact Factor: 3.231**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
  • PubMed NLM ID: 101705590

Search Our Journal

Journal Indexed In

Articles in PubMed

NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Case Report of Pathologically Confirmed Complete Response of Metastatic Breast Cancer after Long Term Experimental Antiangiogenic Treatment as Addition to Standard Therapeutic Approach
 Abstract  PDF  Full Text
An Unusual Case of Papillary Thyroid Carcinoma with Solitary Cerebral Metastases Mimicking Cavernous Hemangioma
 Abstract  PDF  Full Text
View More...